Diazabicyclic compounds useful in the treatment of CNS and other disorders

A compound of formula I

• wherein:
• A=CR1 or N,
• B=CR2 or N,
• D=CR3 or N,
• E=CR4 or N and
• F=CR5 or N;
• and the maximum number of nitrogen atoms amongst A, B, D, E, and F is two;
• where m=1 and n=2;
• where each R1, R2, R3, R4 and R5 is independently selected from F, Cl, Br, I, nitro, cyano, CF3, —NR6R7, —NR6C(═O)R7, —NR6C(═O)NR7R8, —NR6C(═O)OR7, —OR6, —OC(═O)R6, —OC(═O)OR6, —OC(═O)NR6R7, —OC(═O)SR6, —C(═O)OR6, —C(═O)R6, —C(═O)NR6R7, —SR6, —S(═O)R6, and a substituent from the definition of R6;
• each R6, R7, and R8 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11)aryl, and 5-12 membered heteroaryl;
• wherein each R6, R7, and R8 is optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF3, —NR9R10, —NR9C(═O)R10, —NR9C(═O)NR10OR11, —NR9C(═O)OR10, —NR9S(═O)2R10, —NR9S(═O)2NR10R11, —OR9, —OC(═O)R9, —OC(═O)OR9, —OC(═O)NR9R10, —OC(═O)SR9, —C(═O)OR9, —C(═O)R9, —C(═O)NR9R10, —SR9, —S(═O)R9, —S(═O)2R9, —S(═O)2NR9R10 and R9;
• or R1 and R2, or R2 and R3, or R3 and R4, or R4 and R5, may form another 6-membered aromatic or heteroaromatic ring sharing A and B, or B and D, or D and E, or E and F, respectively, and may be optionally substituted with from one to four substituents independently selected from the group of radicals set forth in the definition of R6, R7 and R8 above;
• each R9, R10 and R11 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, (C6-C11)aryl or 5-12 membered heteroaryl;
• wherein each R9, R10 and R11 is optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, nitro, cyano, CF3, —NR12R13, —NR12C(═O)R13, —NR12C(═O)NR13R14, —NR12C(═O)OR13, —NR12S(═O)2R13, —NR12S(═O)2NR13R14, —OR12, —OC(═O)R12, —OC(═O)OR12, —OC(═O)NR12R13, —OC(═O)SR12, —C(═O)OR12, —C(═O)R12, —C(═O)NR12R13, —SR12, —S(═O)R12, —S(═O)2R12, —S(═O)2NR12R13 and R12;
• each R12, R13, and R14 is independently selected from H, straight chain or branched (C1-C8)alkyl, straight chain or branched (C2-C8)alkenyl, straight chain or branched (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C6-C11)aryl and (5-12 membered) heteroaryl;
• or an enantiomeric, diastereomeric, or tautomeric isomers thereof or a pharmaceutically acceptable salts thereof.